Skip to content

Assessment of the predictive value of anti-beta1AR and anti-L-CaC antibodies in the evolution to dilated cardiomyopathy in patients with acute viral myocarditis

DCM antimyocardial antibody diagnostic kit study--assessment of the predictive value of anti-beta1AR and anti-L-CaC antibodies in the evolution to dilated cardiomyopathy in patients with acute viral myocarditis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093872
Enrollment
Unknown
Registered
2024-12-13
Start date
2024-12-15
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Viral myocarditis

Interventions

Exposed group/non-exposed group:Anti-Heart Autoantibody Test Results: Negative/Positive

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meets VMC diagnostic criteria; 2. The onset time of clinical symptoms shall not exceed 30 days; 3. Age>=18 years old and<=75 years old; 4. The subjects or their legal guardians are fully informed of the nature and risks of this study, voluntarily participate, and sign an informed consent form;

Exclusion criteria

Exclusion criteria: 1.Serious uncontrolled infection at enrolment ('uncontrolled' is defined as signs and symptoms of infection that persist without improvement despite antimicrobial or other treatment); 2.Uncontrolled active bleeding at enrollment; 3.Systemic autoimmune disease such as systemic lupus erythematosus or diagnosed immunodeficiency disease at enrollment; 4.Pregnancy or breastfeeding; 5.Combination of serious diseases affecting survival, such as tumors, with a life expectancy shorter than 3 months; 6.Patients with poor compliance who are unable to complete the full course of the study; 7.Other conditions (e.g., overstimulation, sensitivity, cognitive impairment, mental illness, or substance abuse/addiction) that, in the judgment of the investigator, may increase the risk to the subject or interfere with the clinical study and judgment of the results.

Design outcomes

Primary

MeasureTime frame
Incidence of evolution to DCM in patients positive for anti-ß1AR antibodies and anti-L-CaC antibodies;

Secondary

MeasureTime frame
All-Cause Death, Rehospitalization for Heart Failure, or Sudden Death in Patients Positive for Anti-ß1AR Antibodies and Anti-L-CaC Antibodies;

Countries

China

Contacts

Public ContactJing Yuan

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

yhelen13@aliyun.com+86 27 85726009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026